Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1B | Q92523 | 1/20 | 0.67 |
| ▸ | CES2 | O00748 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11139630 | 0.81 | CPT1B (0.65) | CPT1BCES2CA1CA2CA12 | |
| SCHEMBL491263 | 0.81 | CES2 (0.62) | CES2CA1CA2CA12CA7 | |
| SCHEMBL593133 | 0.80 | CPT1B (1.00) | CPT1BCES2CA1CA2CA12 | |
| SCHEMBL31146749 | 0.80 | CES2 (0.62) | CES2MAPTHTTLMNAPKM | |
| SCHEMBL10405285 | 0.80 | CPT1B (0.41) | CPT1BCES2MAPTHTTLMNA | |
| SCHEMBL10918347 | 0.80 | CES2 (0.62) | CPT1BCES2CA1CA2MAPT | |
| SCHEMBL7824195 | 0.80 | CES2 (0.62) | CPT1BCES2CA1CA2HTT | |
| SCHEMBL8120050 | 0.79 | CES2 (0.59) | CES2CA1CA2CA12CA7 | |
| SCHEMBL9043671 | 0.78 | CPT1B (0.95) | CPT1BCES2CA1CA2CA12 | |
| SCHEMBL181662 | 0.77 | CES2 (0.79) | CPT1BCES2CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102816067-A | 4-hydroxybenzoylacrylic acid derivative, preparation method thereof and application | INST MEDICINAL BIOTECHNOLOGY | 2012-12-12 | — | — | CN | claimed |
| CN-114808548-B | High partial discharge insulating material for new energy automobile oil-cooled motor and preparation method thereof | 瑞安复合材料(深圳)有限公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-114808548-A | High partial discharge insulating material for new energy automobile oil-cooled motor and preparation method thereof | 瑞安复合材料(深圳)有限公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-2690095-A1 | Aryl gpr120 receptor agonists and uses thereof | Camabay Therapeutics, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| CN-102816067-A | 4-hydroxybenzoylacrylic acid derivative, preparation method thereof and application | INST MEDICINAL BIOTECHNOLOGY | 2012-12-12 | — | — | CN | disclosed |
| CN-102816067-A | 4-hydroxybenzoylacrylic acid derivative, preparation method thereof and application | INST MEDICINAL BIOTECHNOLOGY | 2012-12-12 | — | — | CN | disclosed |
| CN-102816067-A | 4-hydroxybenzoylacrylic acid derivative, preparation method thereof and application | INST MEDICINAL BIOTECHNOLOGY | 2012-12-12 | — | — | CN | disclosed |
| EP-2350016-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | CPT1B 466/4885CES2 1759/4885CA1 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.